Hypofractionated Radiotherapy Dose Scheme and Application of New Techniques Are Associated to a Lower Incidence of Radiation Pneumonitis in Breast Cancer Patients

Byung Min Lee¹, Jee Suk Chang¹, Se Young Kim¹, Ki Chang Keum¹, Chang-Ok Suh² and Yong Bae Kim¹*

¹Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, South Korea, ²Department of Radiation Oncology, CHA Bundang Medical Center, CHA University, Bundang-gu, South Korea

Purpose: Radiation pneumonitis (RP) is one of the most severe toxicities experienced by patients with breast cancer after radiotherapy (RT). RT fractionation schemes and techniques for breast cancer have undergone numerous changes over the past decades. This study aimed to investigate the incidence of RP as a function of such changes in patients with breast cancer undergoing RT and to identify dosimetric markers that predict the risk of this adverse event.

Methods and Materials: We identified 1,847 women with breast cancer who received adjuvant RT at our institution between 2015 and 2017. The RT technique was individually tailored based on each patient’s clinicopathological features. Deep inspiration breath hold technique or prone positioning were used for patients who underwent left whole-breast irradiation for cardiac sparing, while those requiring regional lymph node irradiation underwent volumetric-modulated arc therapy (VMAT).

Results: Of 1,847 patients who received RT, 21.2% received the conventional dose scheme, while 78.8% received the hypofractionated dose scheme (mostly 40 Gy in 15 fractions). The median follow-up period was 14.5 months, and the overall RP rate was 2.1%. The irradiated organ at risk was corrected concerning biologically equivalent dose. The ipsilateral lung V₃₀ in equivalent dose in 2 Gy (EQD2) was the most significant dosimetric factor associated with RP development. Administering RT using VMAT, and hypofractionated dose scheme significantly reduced ipsilateral lung V₃₀.

Conclusions: Application of new RT techniques and hypofractionated scheme significantly reduce the ipsilateral lung dose. Our data demonstrated that ipsilateral lung V₃₀ in EQD2 is the most relevant dosimetric predictor of RP in patients with breast cancer.

Keywords: radiation pneumonitis, radiotherapy, breast cancer, hypofractionation, lung dosimetry
INTRODUCTION

Radiation pneumonitis (RP) is one of the most severe toxicities caused by radiotherapy (RT) in patients with breast cancer. Although sometimes fatal, particularly in elderly patients or those with medical comorbidities, most symptoms of RP can be resolved with steroid-based medications. In the era of two-dimensional conventional RT, the central lung distance, defined as the distance between the midpoint of the posterior field and the chest wall, was used as an indicator of RP (1, 2). After the introduction of treatment planning based on three-dimensional conformal RT (3D CRT), studies have aimed to identify the dosimetric parameters of the lung that predict RP following RT for breast cancer. However, such studies remain inadequate for clinical utility (3, 4).

There has been an important paradigm shift in RT for breast cancer over the past 20 years. First, hypofractionated dose scheme emerged as a new standard treatment for this disease. Several prospective randomized trials demonstrated that the hypofractionation RT is non-inferior to conventional fractionated RT with respect to treatment outcomes and toxicities after breast conserving surgery. Although hypofractionation RT after mastectomy is not standard of care yet, recent prospective trial has shown non-inferior results compared to conventional RT (5). More radiation oncologists have adopted such abbreviated RT methods because of their convenience and cost-effectiveness (6–9). Along with hypofractionated RT, some other techniques that have become available include volumetric-modulated arc therapy (VMAT), deep inspiration breath-hold (DIBH), and prone positioning.

In this study, we aimed to investigate the incidence of RP and identify the dosimetric markers that predict the risk of this adverse effect as a function of changes in hypofractionated dose schemes and application of new RT techniques used to treat breast cancer.

MATERIALS AND METHODS

Patients

We identified patients who underwent adjuvant RT following surgery for breast cancer at our institution between January 2015 and December 2017 using a prospectively collected registry (n = 2,130). We excluded patients who had distant metastases at the time of their diagnosis (n = 42), those who did not visit at regular follow-up (n = 114), and those who were followed at other hospitals (n = 127). Finally, 1,847 patients who met the eligibility criteria were included in our study cohort. We reviewed the medical charts of all patients to determine the incidence of RP. This study was approved by the institutional review board of Severance hospital (4-2018-0663).

Treatment

We performed computed tomography (CT) simulation (SOMATOM sensation; Siemens, Erlangen, Germany) with 3 mm-thick slices for all patients. For immobilization, patients positioned their ipsilateral arms in abduction and used a thermoplastic immobilization system (Type-S; Medtec, Alton, IA, USA). Per our institutional protocol, the irradiation technique was optimized for each individual to minimize the dose to the heart while maximizing target dose homogeneity. Patients with large, pendulous, or ptotic breasts were placed in the prone position to avoid skin reactions at the inframammary fold. For cancer of the left breast, the DIBH technique was applied to displace the heart from the chest wall, as described previously (10); patients were instructed to apply the Achees breathing monitoring device (APEX Medical, Tokyo, Japan) during DIBH. If the distance between the heart and chest wall was sufficient to lower the heart dose using DIBH by inflating the lung volume, we performed RT using the DIBH technique. Due to the setup uncertainties in prone positioning, we underwent daily cone beam CT during RT. However, if the heart was not sufficiently spared by DIBH or if internal mammary node (IMN) irradiation (IMNI) was required, we performed RT with VMAT for cardiac sparing.

For 3D CRT, target volumes were delineated based on palpating breast tissue and adding a margin; the border of the intact breast and treatment planning for 3D CRT was specified as described elsewhere (11). Regional lymph node irradiation (RNI), including that of the internal mammary, axillary, and supraclavicular lymph nodes, was recommended to patients with metastatic nodes or those with high-risk N0 breast cancer (i.e., tumor sizes larger than 2 cm, high-grade tumors, and estrogen receptor-negative tumors) based on two large scale randomized trials (12, 13). The partial wide tangent field technique was used to cover the entire breast as well as the IMNs. The supraclavicular and axillary lymph nodes were irradiated using a separate beam that did not overlap with that of the breast field. In patients who had undergone mastectomy, the chest wall and regional nodes were irradiated using the reverse hockey stick technique as described elsewhere (14). Since June 2015, we performed hypofractionation in patients who received mastectomy.

For VMAT, target volumes and organs at risk were contoured based on European Society for Radiotherapy and Oncology guidelines, which was validated using both single-center and multi-center datasets in Korea (15). For patients with T4 stage or N2-N3 stage, we followed the Radiation Therapy Oncology Group breast cancer target guidelines. For VMAT planning, two partial arcs were used limiting the unnecessary arc segments without compromising dose quality. Plan generation and dose calculation were performed using the RayStation treatment planning system (version 5.0, RaySearch, Stockholm, Sweden). For treatment, 6 MV photon beams emitted from a linear accelerator (Versa HD, Elekta, Stockholm, Sweden) were used. The 95% isodose encompassed the entire planning target volume, and volumes in target areas receiving over 107% of the prescribed dose were minimized. The planning requirements for organ at risk were as follows: ipsilateral lung V5 <50%, V10 <35%, V20 <20% (Vx defined as the percentage of the total volume exceeding x Gy), mean heart dose <3 Gy, mean left coronary artery dose <6 Gy (maximum point dose [Dmax] <10 Gy), mean contralateral breast dose <2 Gy, esophagus Dmax <12 Gy, and mean thyroid dose <3 Gy. We concerns the esophagus and thyroid to reduce radiation induced esophagitis and hypothyroidism. Cone-beam CT images were obtained daily.
| TABLE 1 | Patient characteristics and treatment characteristics. |
|---------------------------------|---------------------------------|---------------------------------|
|                                  | CF group | HF group |                                  |
| No. of patients | % | No. of patients | % | No. of patients | % | p |
| Age (Year) | | | | | | 0.41 |
| <51 | 908 | 49.2% | 200 | 51.0% | 708 | 48.7% |
| ≥51 | 939 | 50.8% | 192 | 49.0% | 747 | 51.3% |
| Pathology | | | | | | 0.56 |
| Ductal carcinoma in situ | 254 | 14.1% | 59 | 15.1% | 195 | 13.4% |
| Invasive ductal carcinoma | 1,327 | 71.7% | 283 | 72.2% | 1,044 | 71.8% |
| Invasive lobular carcinoma | 85 | 4.6% | 12 | 3.1% | 71 | 4.9% |
| Mucinous carcinoma | 36 | 1.9% | 15 | 3.8% | 21 | 1.4% |
| Tubular carcinoma | 43 | 2.3% | 10 | 2.6% | 33 | 2.3% |
| Stage | | | | | | 0.08 |
| 0 | 261 | 14.5% | 55 | 14.0% | 206 | 14.2% |
| I | 740 | 40.1% | 171 | 43.6% | 569 | 39.1% |
| II | 592 | 31.8% | 110 | 28.1% | 482 | 33.1% |
| III | 253 | 13.6% | 56 | 14.3% | 197 | 13.5% |
| Surgery | | | | | | 0.01 |
| Breast conserving mastectomy | 1,485 | 80.4% | 297 | 75.8% | 1,188 | 81.6% |
| Mastectomy | 362 | 19.6% | 95 | 24.2% | 267 | 18.4% |
| Lung disease* | | | | | | 0.94 |
| Yes | 9 | 0.5% | 2 | 0.5% | 7 | 0.5% |
| No | 1,838 | 99.5% | 390 | 99.5% | 1,488 | 99.5% |
| Smoking history | | | | | | 0.45 |
| Yes | 73 | 4.2% | 13 | 3.5% | 60 | 4.4% |
| No | 1,728 | 95.8% | 358 | 96.5% | 1,370 | 95.6% |
| Regional LN irradiation | | | | | | 0.08 |
| Yes (SCL+IMN+AXL) | 712 | 38.5% | 166 | 42.3% | 546 | 37.5% |
| No | 1135 | 61.5% | 226 | 57.7% | 909 | 62.5% |
| Chemotherapy | | | | | | 0.52 |
| Yes | | | | | | |
| Neoadjuvant CTx | 402 | 21.8% | 89 | 22.7% | 313 | 21.5% |
| Adjuvant CTx | 557 | 30.2% | 109 | 27.8% | 448 | 30.8% |
| No | 888 | 48.1% | 194 | 49.5% | 694 | 47.7% |
| Hormone therapy | | | | | | 0.73 |
| Yes | 1,297 | 70.2% | 278 | 70.9% | 1,019 | 70.0% |
| No | 550 | 29.8% | 114 | 29.1% | 436 | 30.0% |
| RT technique | | | | | | <0.001 |
| Free-breathing | 1,258 | 68.1% | | | | |
| FIF | 226 | 12.2% | 11 | 2.8% | 215 | 14.8% |
| Wedge | 194 | 10.5% | 178 | 45.4% | 16 | 1.1% |
| RHT | 13 | 0.7% | 13 | 3.3% | 0 | 0.0% |
| VMAT | 825 | 44.7% | 8 | 2.0% | 817 | 56.2% |
| DIBH | 488 | 26.4% | | | | |
| FIF | 322 | 17.4% | 22 | 5.6% | 300 | 20.6% |
| Wedge | 164 | 8.9% | 153 | 39.0% | 11 | 0.8% |
| RHT | 2 | 0.1% | 2 | 0.5% | 0 | 0.0% |
| Prone | 101 | 5.5% | | | | |
| FIF | 97 | 5.3% | 4 | 1.0% | 93 | 6.4% |
| Wedge | 4 | 0.2% | 1 | 0.3% | 3 | 0.2% |

*COPD, ILD were included. CF, Conventional fractionation; HF, Hypofractionation; SCL, SuprACLavicular lymph node; IMN, Internal mammary lymph node; AXL, Axillary lymph node; CTx, Chemotherapy; FIF, Field in field; RHT, Reverse hockey stick; VMAT, Volumetric-modulated arc therapy; BCS, Breast-conserving surgery.
to verify appropriate patient set-up and minimize positioning errors. During the study period, three different fractionation schedules were used: either 40.05 Gy in 15 fractions ($n = 1,055, 57.1\%$), or 42.56 Gy in 16 fractions ($n = 400, 21.7\%$) for hypofractionation and 50.4 Gy in 28 fractions ($n = 392, 21.2\%$) schedule for conventional fractionation.

For tumor bed boost, 9 Gy in 5 fractions was applied in conventional fractionation ($n = 297, 20.8\%$). The tumor bed boost in hypofractionated RT differed depending on RT modalities. In case that patients received RT using 3D CRT in hypofractionation, 10 Gy in 5 fractions ($n = 541, 37.9\%$) was applied. The electron beams were used for boost with 3D CRT. For patients treated by VMAT, the tumor bed boost was performed using simultaneous integrated boost. The simultaneous integrated boost dose was determined based on RTOG 1005 protocol. Total dose of 48 Gy in 15 fractions was applied to tumor bed while total dose of 40.05 Gy in 15 fractions was given to the whole breast or whole breast plus regional LN ($n = 373, 26.2\%$).

### Analysis

The primary endpoint was the occurrence of symptomatic RP, defined as respiratory symptoms (e.g., dyspnea, non-productive cough) with correlated radiologic images (e.g., chest radiography and CT). The RP was graded using common terminology criteria for adverse events version 5.0. Radiation oncologists prescribed oral prednisolone until symptoms were relieved. To evaluate the factors affecting the occurrence of RP, univariate and multivariate analyses using Cox proportional hazards models were performed. In multivariate analysis, the factors significant ($p < 0.05$) in univariate analysis were used. The factors related to RP in other studies were also included for multivariate analysis. The receiver operating characteristic (ROC) and area under the curve analyses were used to identify the optimal cutoff values that best predict the occurrence of RP. The comparison between hypofractionation group and conventional fractionation group was performed using chi-squared test. The logistic regression analysis was used to evaluate the factors associated with the lung dose parameters.

For dosimetric analysis, the planning data of all the patients were transferred into the MIM software (version 6.7.14; Cleveland, OH, USA) for multiple-plan comparison. To analyze the ipsilateral lung dose parameter, we collected the ipsilateral mean lung dose, $V_{5}$, $V_{10}$, $V_{15}$, $V_{20}$, $V_{30}$, and $V_{40}$. The ipsilateral lung dose parameters were converted into equivalent dose in 2 Gy (EQD2) with $\alpha/\beta$ ratio of 3 Gy to correct for hypofractionation. All tests were conducted by using either the SPSS software version 20.0 (IBM Corp., Armonk, New York, USA) or R version 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria).

### Table 2

| IMN (−) | Free-breathing 3D CRT | DIBH 3D CRT | Prone 3D CRT | Volumetric arc therapy | IMN (+) | Free-breathing 3D CRT | DIBH 3D CRT | Volumetric arc therapy |
|---------|------------------------|-------------|-------------|------------------------|---------|------------------------|-------------|------------------------|
| No. of patients | 307 | 304 | 101 | 423 | 130 | 184 | 398 |
| Mean lung dose | | | | | | | |
| Median | 6.50 | 5.71 | 1.16 | 5.70 | 16.24 | 11.20 | 7.56 |
| IQR | 4.64–8.32 | 4.30–8.22 | 0.52–2.51 | 4.92–6.76 | 11.24–19.82 | 8.9–15.24 | 6.73–8.33 |
| $V_5$ | 22.17 | 21.01 | 4.03 | 26.99 | 54.11 | 41.30 | 34.62 |
| IQR | 16.54–30.7 | 15.9–30.00 | 0.88–8.05 | 22.92–31.14 | 43.32–62.21 | 35.67–51.58 | 30.91–38.28 |
| $V_{10}$ | 17.34 | 15.60 | 2.47 | 17.24 | 44.83 | 33.75 | 23.49 |
| IQR | 12.81–21.54 | 12.38–21.2 | 0.33–6.00 | 14.50–20.40 | 32.74–51.04 | 27.95–41.18 | 20.75–26.55 |
| $V_{15}$ | 14.79 | 13.07 | 1.77 | 12.00 | 40.09 | 30.10 | 17.76 |
| IQR | 10.94–18.42 | 10.15–17.88 | 0.17–4.54 | 9.95–15.08 | 27.91–45.49 | 23.19–37.02 | 15.40–20.08 |
| $V_{20}$ | 12.86 | 11.20 | 1.35 | 8.54 | 36.35 | 27.13 | 13.33 |
| IQR | 9.38–16.42 | 8.38–15.78 | 0.07–3.74 | 6.69–11.25 | 24.80–42.00 | 19.70–33.69 | 11.19–15.30 |
| $V_{30}$ | 9.59 | 7.85 | 0.66 | 3.60 | 29.02 | 18.26 | 6.30 |
| IQR | 6.33–13.09 | 5.19–12.08 | 0.00–2.00 | 2.10–5.62 | 15.00–35.34 | 11.25–24.62 | 4.37–8.45 |
| $V_{40}$ | 3.26 | 1.85 | 0.03 | 0.36 | 14.00 | 2.95 | 1.13 |
| IQR | 0.83–8.56 | 0.18–7.23 | 0.00–0.37 | 0.05–1.16 | 2.10–22.43 | 0.87–11.70 | 0.60–2.14 |

IMN, Internal mammary lymph node; 3D CRT, 3-Dimensional conformal radiation therapy; DIBH, Deep inspiration breath-hold; VMAT, Volumetric-modulated arc therapy; IQR, Interquartile range.
RESULTS

Patient Characteristics
The patient and tumor characteristics are summarized in Table 1. Approximately 85% of the patients had early breast cancer (stages 0–2). In total, 38.5% received RNI and 51.9% received either neoadjuvant or adjuvant chemotherapy. Adjuvant RT was performed either via the conventional dose scheme (21.2%) or the hypofractionated dose scheme (78.8%); 44.7% of patients underwent adjuvant RT using VMAT.

We also compared the patient and tumor characteristics between the conventional fractionation group and hypofractionation group (Table 1). Most of the variables were well-balanced between two groups except for the method of surgery and the techniques used for RT. More patients in the hypofractionated group received breast conserving surgery. Also, most of the patients treated with VMAT underwent hypofractionated RT.

RP Incidence
RP occurred in 40 patients (2.1%) within a median follow-up period of 14.5 months. The commonest symptom was a mild dry cough; few patients also experienced other symptoms such as shortness of breath. Patients experiencing RP symptoms were prescribed steroids, following which these symptoms resolved. None of the patients developed RP grade ≥3. Symptomatic RP

FIGURE 1 | Comparison of lung dose according to the radiotherapy modality without (A) and with (B) internal mammary lymph node irradiation. 3D CRT, three-dimensional conformal radiotherapy; DIBH, deep inspiration breath hold; Vχ, percentage of the total volume exceeding χ Gy.

FIGURE 2 | Comparison of the lung dose-volume histogram between patients who developed radiation pneumonitis and those who did not.
that in patients using other techniques. In patients who did not undergo IMNI, the lung $V_{30}$ and $V_{40}$ were significantly lower in patients undergoing VMAT than in those in patients undergoing other techniques, while the lung $V_{5}$ was higher in patients undergoing VMAT (Figure 1A). For patients who did undergo IMNI, the VMAT group showed the lowest mean lung dose (Figure 1B).

Moreover, we found that patients with RP showed higher dose-volume histogram parameter values in all areas than those without RP. Among these individual parameters, ipsilateral lung $V_{30}$ showed the largest difference between these two patient groups (Figure 2).

**RPA**

We performed RPA to determine the factors associated with RP. Among various dosimetric parameters, the ipsilateral lung $V_{30}$ in EQD2 >10% was associated with significantly higher RP rates than those of ipsilateral lung $V_{30}$ in EQD2 ≤10%. The RP occurred in 4.6% in patients with ipsilateral lung $V_{30}$ more than 10% while only 1.4% of patients experienced RP when ipsilateral lung $V_{30}$ was <10% (Figure 3).

**Dosimetric Analysis**

The mean lung dose, ipsilateral lung $V_{5}$, $V_{10}$, $V_{15}$, $V_{20}$, $V_{30}$, and $V_{40}$ were all significantly associated with RP. The largest area under the ROC curve was that of the ipsilateral lung $V_{30}$ (Figure 4). Univariate analysis showed that hormone treatment, fractionation schedule, RT technique, and the ipsilateral lung $V_{30}$ significantly affected RP. On multivariate analysis, patients with ipsilateral lung $V_{30}$ larger than 10% had a significantly higher rate of RP than those with ipsilateral lung $V_{30}$ <10% (Table 3). Among the RT techniques, fractionation schemes, and IMN irradiation, VMAT (odds ratio 0.12, 95% CI 0.08–0.17) was a major determinant of lowering ipsilateral lung $V_{30}$ followed by hypofractionation (odds ratio 0.14, 95% CI 0.10–0.19). The IMN
TABLE 3 | Univariate and multivariate analysis of factors associated with symptomatic radiation pneumonitis.

| Radiation pneumonitis rate | HR (95% CI) | p  | Univariate analysis | Multivariate analysis | p  |
|---------------------------|-------------|----|---------------------|-----------------------|----|
| Age (≥51 vs. <51)         | 1.8 vs. 2.5% | 0.69 (0.37–1.29) | 0.25 |
| Lung disease (Yes vs. No) | 11.1 vs. 2.1% | 5.41 (0.74–39.45) | 0.09 |
| Smoking history (Yes vs. No) | 0 vs. 2.1% | 0.05 (0.00–86.13) | 0.42 |
| Chemotherapy (Yes vs. No) | 1.9 vs. 2.5% | 0.90 (0.63–1.29) | 0.58 |
| Chemotherapy regimen      |             |                | 0.09 |
| Taxane based vs. Adriamycin based | 1.1 vs. 2.4% | 0.52 (0.15–1.88) | 0.32 |
| Herceptin based vs. Adriamycin based | 6 vs. 2.4% | 2.06 (0.83–5.13) | 0.12 |
| Hormone therapy (Yes vs. No) | 1.7 vs. 3.3% | 0.50 (0.27–0.94) | 0.03 |
| Regional LN irradiation (Yes vs. No) | 2.4 vs. 2.0% | 1.12 (0.59–2.09) | 0.73 |
| Fraction schedule (Hypofractionation vs. Conventional fractionation) | 1.5 vs. 4.6% | 0.43 (0.23–0.80) | <.01 |
| Ipsilateral lung dose ($V_{30} > 10\%$ vs. $V_{30} \leq 10\%$) | 4.6 vs. 1.4% | 2.93 (1.53–5.62) | <.01 |
| RT technique             |             |                | 0.007 |
| DIBH 3D CRT vs. Free-breathing 3D CRT | 2.5 vs. 5.0% | 0.47 (0.23–0.95) | 0.04 |
| Prone 3D CRT vs. Free-breathing 3D CRT | 0 vs. 5.0% | NR | |
| VMAT vs. Free-breathing 3D CRT | 0.7 vs. 5.0% | 0.22 (0.09–0.55) | 0.001 |

CI, Confidence interval; HR, Hazard ratio; LN, Lymph node; 3D CRT, 3-dimensional conformal radiotherapy; DIBH, Deep inspiration breath hold; VMAT, Volumetric modulated arc therapy; NR, Not reported.

TABLE 4 | Analysis the factor determining the lung $V_{30}$.

| OR (95% CI) | p  | OR (95% CI) | p  |
|-------------|----|-------------|----|
| IMN irradiation (Yes vs. No) | 2.63 (2.15–3.22) | <.001 | 6.59 (4.88–8.92) | <.001 |
| Hypofractionation (Yes vs. No) | 0.07 (0.06–0.10) | <.001 | 0.14 (0.10–0.19) | <.001 |
| VMAT (Yes vs. No) | 0.12 (0.10–0.16) | <.001 | 0.12 (0.08–0.17) | <.001 |
| Prone (Yes vs. No) | NR | NR | |
| DIBH (Yes vs. No) | 0.30 (0.24–0.38) | <.001 | 0.98 (0.73–1.33) | 0.911 |

OR, Odds ratio; CI, Confidence interval; IMN, Internal mammary node; VMAT, Volumetric modulated arc therapy; DIBH, Deep inspiration breath hold; NR, Not reported.

irradiation was the only factor increasing the ipsilateral lung $V_{30}$ (odds ratio 6.59, 95% CI 4.88–8.92) (Table 4).

DISCUSSION

This study investigated the incidence of RP in patients with breast cancer who underwent conventional and hypofractionation RT and identified dosimetric markers that predict the risk of RP. We demonstrated that ipsilateral lung $V_{30}$ is the dosimetric predictor of RP that is the most relevant in patients with breast cancer. The change in RT techniques using VMAT and hypofractionation dose schemes reduce the ipsilateral lung $V_{30}$.

Several studies have shown that the occurrence of RP is affected by both patient-related and treatment-related factors. Patient-related factors that affect the incidence of RP include existing lung disease, poor pulmonary function, and smoking history (16, 17). Meanwhile, treatment-related factors known to affect RP development in patients with lung cancer include radiation dose, irradiated lung volume, schedule of fractionation, and usage of chemotherapy (18–21). However, as patients with breast cancer tend not to have underlying lung diseases or smoking histories with the same frequencies as those with lung cancer, our study revealed no association between patient-related factors and the occurrence of RP. However, treatment-related factors, particularly those related to RT, did affect RP development, as reported previously (11).

In this study, we showed that the hypofractionation dose scheme lowered the ipsilateral lung dose $V_{30}$. It was suggested that the $\alpha/\beta$ ratio for breast tissue ranges from 3 to 4 Gy, which is similar to that of normal tissues (6), and this was later confirmed in the START A, START B, and another Canadian study (8, 22, 23). Hence, hypofractionation has become the standard treatment for breast cancer. While hypofractionation did not significantly affect RP development in our study, the $V_{30}$ of the ipsilateral lung were found to be strong predictors of RP.

We also demonstrated that advances in RT techniques have reduced the incidence rate of RP. Improvements that were designed to reduce the dose to the heart while maintaining RT safety and efficacy include intensity-modulated RT (IMRT), DIBH, and prone positioning; these techniques also significantly
decreased the dose to the lung by more than 50%. The DIBH can lower the dose to the heart, but the coverage of the ipsilateral whole breast planning target volume can be suboptimal. In case that the tumor was located at medial location of the breast, tangent fields are difficult to fully cover tumor bed and avoid the heart simultaneously. Even though the prone positioning for breast enables lowering the dose to the lung and heart, but setup uncertainties exist for prone positioning (24). By contrast, IMRT made it possible to protect the heart and ipsilateral lung without compromising target coverage and set up uncertainties.

Because landmark studies such as the MA 20 and EORTC 22922 trials demonstrated that RNI can reduce the risk of early breast cancer recurrence (12, 13), radiation oncologists increasingly consider its application but remain hesitant owing to the risk of toxicity to the heart and lung. While we perform DIBH and prone positioning for patients at our hospital who are not undergoing RNI, 3D CRT with partially wide tangent fields has been performed in patients requiring RNI, including IMNI. IMRT for breast cancer is widely used today after it became reimbursable by the national insurance program in our country in 2015. Our study showed that IMRT can sufficiently cover the whole breast and regional lymph nodes, particularly IMNs, while effectively reducing lung, and heart toxicity.

The chemotherapy regimen did not affect the incidence of RP in our study. As some chemotherapeutic agents act as sensitizers to radiation, the patients who received chemotherapy could be at higher risk to RP. The article showing that chemotherapy increased the risk of RP demonstrated that sequential chemotherapy diminished the risk of RP as compared to concurrent chemoradiotherapy (25). In our study, none of the patients underwent concurrent chemotherapy during RT. As sequential chemotherapy has minimal impact on development of RP, neither the chemotherapy regimen nor the use of chemotherapy increased the risk of RP in our study.

Sequential tumor bed boost was applied in patients treated with 3D CRT while simultaneous integrated boost was used in patients treated with VMAT. In this study, sequential tumor bed boost dose was not accounted for analysis. However, as electron beams were used for sequential tumor bed boost in case of patients treated with 3D CRT, we believed that the effect of tumor bed boost to the lung dose was negligible.

No significant parameters predicting the occurrence of RP in patients with breast cancer have been identified to date. The 3D CRT technique can reduce the areas receiving low irradiation doses (e.g., the V5 and V10) on the dose-volume histograms but not the areas receiving high doses. By contrast, the VMAT technique can reduce the areas of high RT dose while widening the areas of low irradiation (26). Previous studies in patients with breast cancer showed that V20 lung constraints could markedly reduce RP (27, 28). However, our results also demonstrated that V30 constraints were significantly associated with reduced RP rates in patients with breast cancer.

Our study was limited by its retrospective design and single-institution analysis. Some unbalance existed in patient characteristics between hypofractionated and conventional fractionated RT group, as the surgical method and RT techniques were significantly different between two groups. Also, the number of patients with RNI and without RNI differ largely. Although most of the factors were well-balanced between two groups, careful interpretation of results is needed. As such, external validation is necessary to confirm our findings.

In conclusion, our study demonstrated that the hypofractionation dose scheme and RT techniques such as VMAT can reduce the radiation dose and potentially the incidence of RP. Although external validation is still required, we clearly showed that ipsilateral lung V30 in EQD2 is reliable dosimetric predictors of RP in patients with breast cancer.

DATA AVAILABILITY STATEMENT

The datasets generated for this study are available on request to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by institutional review board of Severance hospital (4-2018-0663). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR’S NOTE

This study was presented at the 60th Annual meeting of the American Society for Radiation Oncology (ASTRO), October 21–24, 2018, San Antonio, Texas.

AUTHOR CONTRIBUTIONS

JC and YK: study concept and design. SK, KK, C-OS, and YK: data acquisition and quality control of data. BL, JC, and YK: data analysis and interpretation. BL and JC: manuscript preparation. JC and YK: manuscript review.

REFERENCES

1. Neal AJ, Yarnold JR. Estimating the volume of lung irradiated during tangential breast irradiation using the central lung distance. Br J Radiol. (1995) 68:1004–8. doi: 10.1259/0007-1285-68-813-1004

2. Das IJ, Cheng EC, Freedman G, Fowble B. Lung and heart dose volume analyses with CT simulator in radiation treatment of breast cancer. Int J Radiat Oncol Biol Phys. (1998) 42:11–9. doi: 10.1016/S0360-3016(98)00200-4

3. Kimsey FC, Mendenhall NP, Ewald LM, Coons TS, Layon AJ. Is radiation treatment volume a predictor for acute or late effect on pulmonary-function? – a prospective-study of patients treated with breast-conserving surgery and postoperative irradiation. Cancer. (1994) 73:2549–55. doi: 10.1002/1097-0142(19940515)73:10<2549::AID-CNCR2820731016>3.0.CO;2-N

4. Marks LB, Bentzen SM, Deasy JO, Kong FM, Bradley JD, Vogelius IS, et al. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys. (2010) 76(3 Suppl):S70–6. doi: 10.1016/j.ijrobp.2009.06.091
5. Wang SL, Fang H, Song YW, Wang WH, Hu C, Liu YP, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. *Lancet Oncol.* (2019) 20:352–60. doi: 10.1016/S1470-2045(18)30813-1

6. Yarnold J, Ashton A, Bliss J, Homewood J, Harper C, Hansson J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. *Radiother Oncol.* (2005) 75:9–17. doi: 10.1016/j.radonc.2005.01.005

7. Owen JR, Ashton A, Bliss JM, Homewood J, Harper C, Hanson J, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. *Lancet Oncol.* (2006) 7:467–71. doi: 10.1016/S1470-2045(06)70699-4

8. Group ST, Bentzen SM, Aigrall RK, Aird EG, Barrett JM, Barrett-Lee PJ, et al. The UK standardisation of breast radiotherapy. (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer. A randomised trial. *Lancet.* (2008) 371:1098–107. doi: 10.1016/S0140-6736(08)60348-7

9. Haviland JS, Owen JR, Dwars JA, Aigrall RK, Barrett J, Barrett-Lee PJ, et al. The UK standardisation of breast radiotherapy. (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. *Lancet Oncol.* (2013) 14:1086–94. doi: 10.1016/S1470-2045(13)70386-3

10. Lee HY, Chang JS, Lee IJ, Park K, Kim YB, Suh CO, et al. The deep inspiration breath hold technique using Achiies reduces cardiac dose in patients undergoing left-sided breast irradiation. *Radiat Oncol J.* (2013) 31:239–46. doi: 10.3857/roj.2013.31.4.239

11. Lee BM, Chang JS, Cho YU, Park S, Park HS, Kim JY, et al. External validation of IBTR! 2.0 nomogram for prediction of ipsilateral breast tumor recurrence. *Radiat Oncol J.* (2018) 36:139–46. doi: 10.3857/roj.2018.00059

12. Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, et al. The UK standardisation of breast radiotherapy. (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: results of a large retrospective study with 12-year follow-up. *Lancet Oncol.* (2010) 373:197–207. doi: 10.1016/S0140-6736(09)61229-4

13. Owen JR, Ashton A, Bliss J, Homewood J, Harper C, Hanson J, et al. Long-term results of hypofractionated radiation therapy for breast cancer. *Int J Radiat Oncol Biol Phys.* (2006) 65:83–8. doi: 10.1016/j.ijrobp.2006.12.016

14. Chang JS, Byun HK, Kim JW, Lee J, Cho Y, et al. Three-dimensional analysis of patterns of locoregional recurrence after treatment in breast cancer patients: validation of the ESTRO consensus guideline on target volume. *Radiother Oncol.* (2017) 122:24–9. doi: 10.1016/j.radonc.2016.10.016

15. Chang JS, Byun HK, Kim JW, Lee J, Cho Y, et al. Three-dimensional analysis of patterns of locoregional recurrence after treatment in breast cancer patients: validation of the ESTRO consensus guideline on target volume. *Radiother Oncol.* (2017) 122:24–9. doi: 10.1016/j.radonc.2016.10.016

16. Kong FM, Klein EE, Bradley JD, Mansur DB, Taylor ME, Perez CA, et al. The impact of central lung distance, maximal heart distance, and radiation technique on the volumetric dose of the lung and heart for intact breast irradiation. *Int J Radiat Oncol Biol Phys.* (2002) 54:963–71. doi: 10.1016/S0360-3016(02)03741-0

17. Lind PA, Marks LB, Hardenbergh PH, Clough R, Fan M, Hollis D, et al. Technical factors associated with radiation pneumonitis after local +/- regional radiation therapy for breast cancer. *Int J Radiat Oncol Biol Phys.* (2002) 52:137–43. doi: 10.1016/S0360-3016(01)01715-1

18. Seppenwoolde Y, De Jaeger K, Boersma LJ, Belderbos JS, Lebesque JV. Regional differences in lung radiosensitivity after radiotherapy for non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys.* (2004) 60:748–58. doi: 10.1016/j.ijrobp.2004.04.037

19. Khan MA, Van Dyk J, Yeung IW, Hill RP. Partial volume rat lung irradiation: assessment of early DNA damage in different lung regions and effect of radical scavengers. *Radiother Oncol.* (2003) 66:95–102. doi: 10.1016/S0167-8140(02)00325-0

20. Kahan Z, Czenki M, Varga Z, Szil E, Cserhati A, Balogh A, et al. The risk of early and late lung sequelae after conformal radiotherapy in breast cancer patients. *Int J Radiat Oncol Biol Phys.* (2007) 68:673–81. doi: 10.1016/j.ijrobp.2006.12.016

21. Tsujino K, Hirota S, Endo M, Obayashi K, Kotani Y, Satouchi M, et al. Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. *Int J Radiat Oncol Biol Phys.* (2005) 55:110–15. doi: 10.1016/j.ijrobp.2003.10.005

22. Group ST, Bentzen SM, Aigrall RK, Aird EG, Barrett JM, Barrett-Lee PJ, et al. The UK standardisation of breast radiotherapy. (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: results of a large retrospective study with 12-year follow-up. *Lancet Oncol.* (2010) 36:83–4. doi: 10.3857/roj.2010.001005

23. Whelan TJ, Pignol JP, Levine MN, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. *N Engl J Med.* (2010) 362:513–20. doi: 10.1056/NEJMoa0906260

24. Kawamura M, Maeda Y, Takamatsu S, Tamamura H, Yamamoto K, Tameshige Y, et al. Development of the breast immobilization system in prone setup: the risk of bra in prone position to eliminate the breast setup error. *Int J Radiat Oncol Biol Phys.* (2014) 90:S224–S. doi: 10.1016/j.ijrobp.2014.05.808

25. Vogelius IR, Bentzen SM. A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. *Acta Oncol.* (2012) 51:975–83. doi: 10.3109/0284186X.2012.718093

26. Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. *Int J Radiat Oncol Biol Phys.* (2003) 56:83–8. doi: 10.1016/S0360-3016(03)00073-7

27. Blom Goldman U, Anderson M, Wennberg B, Lind P. Radiation pneumonitis and pulmonary function with lung dose-volume constraints in breast cancer irradiation. *J Radiother Pract.* (2014) 13:211–7. doi: 10.1177/1460396913500228

28. Lingos TI, Recht A, Vicini F, Abner A, Silver B, Harris JR. Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy. *Int J Radiat Oncol Biol Phys.* (1991) 21:355–60. doi: 10.1016/0360-3016(91)90782-Y

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Lee, Chang, Kim, Keum, Suh and Kim. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.